Lakefront Biotherapeutics (LKFT) Total Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Total Current Liabilities for 13 consecutive years, with $114.3 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities fell 77.02% year-over-year to $114.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.3 million (down 77.02% YoY) and the FY2025 annual result came in at $174.0 million, down 54.38% from the prior year.
• Total Current Liabilities declined to $114.3 million in Q1 2026 per LKFT's latest filing, from $174.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for LKFT reached as high as $640.5 million in Q1 2022 and fell as low as $114.3 million in Q1 2026.
• A 5-year average of $438.5 million and a median of $458.5 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2025 — Total Current Liabilities climbed 14.35% — and 2026, when it plunged 77.02%.
• Year by year, Total Current Liabilities stood at $594.6 million in 2022, then dropped by 18.05% to $487.3 million in 2023, then retreated by 21.75% to $381.3 million in 2024, then sank by 54.38% to $174.0 million in 2025, then tumbled by 34.3% to $114.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $114.3 million, $174.0 million, and $417.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.